| Ident. | Authors (with country if any) | Title |
|---|
| 000131 |
Christine Klein [Canada, Allemagne] ; Rosalind Chuang [Canada] ; Connie Marras [Canada] ; Anthony E. Lang [Canada] | The curious case of phenocopies in families with genetic Parkinson's disease |
| 000186 |
Connie Marras [Canada] ; Michael P. Mcdermott [États-Unis] ; Ken Marek [États-Unis] ; Paula Rochon [Canada] ; Gary Naglie [Canada] ; Caroline M. Tanner [États-Unis] ; Alice Rudolph [États-Unis] ; Ira Shoulson [États-Unis] ; Anthony E. Lang [Canada] | Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts |
| 000208 |
Cristina Sampaio [Portugal] ; Juliana Bronzova [Pays-Bas] ; Robert A. Hauser [États-Unis] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Serge V. Van De Witte [Pays-Bas] ; And Ad Theeuwes [Pays-Bas] | Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double‐blind trials |
| 000379 |
Robert D. Altman [Canada] ; Anthony E. Lang [Canada] ; Ronald B. Postuma [Canada] | Caffeine in Parkinson's disease: A pilot open‐label, dose‐escalation study |
| 000416 |
Anthony E. Lang [Canada] | A critical appraisal of the premotor symptoms of Parkinson's disease: Potential usefulness in early diagnosis and design of neuroprotective trials |
| 000515 |
Shen-Yang Lim [Canada, Malaisie] ; Anthony E. Lang [Canada] | The nonmotor symptoms of Parkinson's disease—An overview |
| 000536 |
Jerrold L. Vitek [États-Unis] ; Kelly E. Lyons [États-Unis] ; Roy Bakay [États-Unis] ; Alim-Louis Benabid [France] ; Guenther Deuschl [Allemagne] ; Mark Hallett [États-Unis] ; Roger Kurlan [États-Unis] ; Joseph J. Pancrazio [États-Unis] ; Ali Rezai [États-Unis] ; Benjamin L. Walter [États-Unis] ; Anthony E. Lang [Canada] | Standard guidelines for publication of deep brain stimulation studies in Parkinson's disease (Guide4DBS‐PD) |
| 000655 |
Elena Moro [Canada] ; Andres M. Lozano [Canada] ; Pierre Pollak [France] ; Yves Agid [France] ; Stig Rehncrona [Suède] ; Jens Volkmann [Allemagne] ; Jaime Kulisevsky [Espagne] ; Jose A. Obeso [Espagne] ; Alberto Albanese [Italie] ; Marwan I. Hariz [Royaume-Uni, Suède] ; Niall P. Quinn [Royaume-Uni] ; Jans D. Speelman [Pays-Bas] ; Alim-Louis Benabid [France] ; Valerie Fraix [France] ; Alexandre Mendes [France] ; Marie-Laure Welter [France] ; Jean-Luc Houeto [France] ; Philippe Cornu [France] ; Didier Dormont [France] ; Annalena L. Tornqvist [Suède] ; Ron Ekberg [Suède] ; Alfons Schnitzler [Allemagne] ; Lars Timmermann [Allemagne] ; Lars Wojtecki [Allemagne] ; Andres Gironell [Espagne] ; Maria C. Rodriguez-Oroz [Espagne] ; Jorge Guridi [Espagne] ; Anna R. Bentivoglio [Italie] ; Maria F. Contarino [Italie, Pays-Bas] ; Luigi Romito [Italie] ; Massimo Scerrati [Italie] ; Marc Janssens [Pays-Bas] ; Anthony E. Lang [Canada] | Long‐term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease |
| 000738 |
Juliana Bronzova [Pays-Bas] ; Cristina Sampaio [Portugal] ; Robert A. Hauser [États-Unis] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Ad Theeuwes [Pays-Bas] ; Serge V. Van De Witte [Pays-Bas] ; Guus Van Scharrenburg [Pays-Bas] | Double‐blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease |
| 000790 |
Steven R. Schwid [États-Unis] ; Janice Bausch [États-Unis] ; David Oakes [États-Unis] ; Lynn Schuchter [États-Unis] ; Caroline Tanner [États-Unis] ; Misser Forrest [Danemark] ; Anthony E. Lang [Canada] ; Ira Shoulson [États-Unis] | Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease |
| 000B78 |
Bernard Ravina [États-Unis] ; Caroline Tanner [États-Unis] ; Diane Dieuliis [États-Unis] ; Shirley Eberly [États-Unis] ; Emily Flagg [États-Unis] ; Wendy R. Galpern [États-Unis] ; Stanley Fahn [États-Unis] ; Christopher G. Goetz [États-Unis] ; Stephen Grate [États-Unis] ; Roger Kurlan [États-Unis] ; Anthony E. Lang [Canada] ; Kenneth Marek [États-Unis] ; Karl Kieburtz [États-Unis] ; David Oakes [États-Unis] ; Robin Elliott [États-Unis] ; Ira Shoulson [États-Unis] | A longitudinal program for biomarker development in Parkinson's disease: A feasibility study |
| 000B80 |
Connie Marras [Canada] ; Anthony E. Lang [Canada] ; Shirley W. Eberly [États-Unis] ; David Oakes [États-Unis] ; Stanley Fahn [États-Unis] ; Steven R. Schwid [États-Unis] ; Christopher Hyson [Canada] ; Ira Shoulson [États-Unis] | A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts |
| 000C56 |
Renato P. Munhoz [Brésil] ; Yosuke Wakutani [Canada] ; Connie Marras [Canada] ; Helio A. Teive [Brésil] ; Salmo Raskin [Brésil] ; Lineu C. Werneck [Brésil] ; Danielle Moreno [Canada] ; Christine Sato [Canada] ; Anthony E. Lang [Canada] ; Ekaterina Rogaeva [Canada] | The G2019S LRRK2 mutation in Brazilian patients with Parkinson's disease: Phenotype in monozygotic twins |
| 000D01 |
Connie Marras [Canada] ; Michael P. Mcdermott [États-Unis] ; Paula A. Rochon [Canada] ; Caroline M. Tanner [États-Unis] ; Gary Naglie [Canada] ; Anthony E. Lang [Canada] | Predictors of deterioration in health‐related quality of life in Parkinson's disease: Results from the DATATOP trial |
| 000E18 |
Shen-Yang Lim [Australie] ; Michael J. Farrell [Australie] ; Stephen J. Gibson [Australie] ; Robert D. Helme [Australie] ; Anthony E. Lang [Canada] ; Andrew H. Evans [Australie] | Do dyskinesia and pain share common pathophysiological mechanisms in Parkinson's disease? |
| 000F43 |
Robert A. Hauser [États-Unis] ; Olivier Rascol [France] ; Amos D. Korczyn [Israël] ; A. Jon Stoessl [Canada] ; Ray L. Watts [États-Unis] ; Werner Poewe [Autriche] ; Peter P. De Deyn [Belgique] ; Anthony E. Lang [Canada] | Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa |
| 000F71 |
Ana Djarmati [Allemagne] ; Miodrag Gužvi [Allemagne, Serbie] ; Anne Grünewald [Allemagne] ; Anthony E. Lang [Canada] ; Peter P. Pramstaller [Italie] ; David K. Simon [États-Unis] ; Angela M. Kaindl [Allemagne] ; Peter Vieregge [Allemagne] ; Anders O. H. Nygren [Pays-Bas] ; Christian Beetz [Allemagne] ; Katja Hedrich [Allemagne] ; Christine Klein [Allemagne] | Rapid and reliable detection of exon rearrangements in various movement disorders genes by multiplex ligation‐dependent probe amplification |
| 001030 |
Panida Piboolnurak [Canada, Thaïlande] ; Anthony E. Lang [Canada] ; Andres M. Lozano [Canada] ; Janis M. Miyasaki [Canada] ; Jean A. Saint-Cyr [Canada] ; Yu-Yan W. Poon [Canada] ; William D. Hutchison [Canada] ; Jonathan O. Dostrovsky [Canada] ; Elena Moro [Canada] | Levodopa response in long‐term bilateral subthalamic stimulation for Parkinson's disease |
| 001116 |
Connie Marras [Canada] ; Alexander Kopp [Canada] ; Feng Qiu [Canada] ; Anthony E. Lang [Canada] ; Kathy Sykora [Canada] ; Kenneth I. Shulman [Canada] ; Paula A. Rochon [Canada] | Antipsychotic use in older adults with Parkinson's disease |
| 001173 |
Susan H. Fox [Canada] ; Anthony E. Lang [Canada] ; Jonathan M. Brotchie [Canada] | Translation of nondopaminergic treatments for levodopa‐induced dyskinesia from MPTP‐lesioned nonhuman primates to phase IIa clinical studies: Keys to success and roads to failure |
| 001194 |
Galit Kleiner-Fisman [États-Unis] ; Jan Herzog [Allemagne] ; David N. Fisman [États-Unis] ; Filippo Tamma [Italie] ; Kelly E. Lyons [États-Unis] ; Rajesh Pahwa [États-Unis] ; Anthony E. Lang [Canada] ; Günther Deuschl [Allemagne] | Subthalamic nucleus deep brain stimulation: Summary and meta‐analysis of outcomes |
| 001236 |
Claire Ardouin [France] ; Valerie Voon [Canada] ; Yulia Worbe [France] ; Nehman Abouazar [France] ; Virginie Czernecki [France] ; Hassan Hosseini [France] ; Antoine Pelissolo [France] ; Elena Moro [Canada] ; Eugénie Lhommée [France] ; Anthony E. Lang [Canada] ; Yves Agid [France] ; Alim-Louis Benabid [France] ; Pierre Pollak [France] ; Luc Mallet [France] ; Paul Krack [France] | Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation |
| 001322 |
Olivier Rascol [France] ; David J. Brooks [Royaume-Uni] ; Amos D. Korczyn [Israël] ; Peter P. De Deyn [Belgique] ; Carl E. Clarke [Royaume-Uni] ; Anthony E. Lang [Canada] ; Mona Abdalla [Royaume-Uni] | Development of dyskinesias in a 5‐year trial of ropinirole and L‐dopa |
| 001327 |
Anthony E. Lang [Canada] ; Jean-Luc Houeto [France] ; Paul Krack [France] ; Cynthia Kubu [États-Unis] ; Kelly E. Lyons [États-Unis] ; Elena Moro [Canada] ; William Ondo [États-Unis] ; Rajesh Pahwa [États-Unis] ; Werner Poewe [Autriche] ; Alexander I. Tröster [États-Unis] ; Ryan Uitti [États-Unis] ; Valerie Voon [Canada, États-Unis] | Deep brain stimulation: Preoperative issues |
| 001792 |
Taresa Stefurak [Canada] ; David Mikulis [Canada] ; Helen Mayberg [Canada] ; Anthony E. Lang [Canada] ; Stephanie Hevenor [Canada] ; Peter Pahapill [États-Unis] ; Jean Saint-Cyr [Canada] ; Andres Lozano [Canada] | Deep brain stimulation for Parkinson's disease dissociates mood and motor circuits: A functional MRI case study |
| 001915 |
Anthony E. Lang [Canada] ; Hakan Widner [Suède] | Deep brain stimulation for Parkinson's disease: Patient selection and evaluation |
| 001923 |
Yun J. Kim [Canada] ; Masanori Ichise [Canada] ; James R. Ballinger [Canada] ; Douglas Vines [Canada] ; Sean S. Erami [Canada] ; Tatsuro Tatschida [Canada] ; Anthony E. Lang [Canada] | Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP |
| 001D88 |
Glenn T. Stebbins [États-Unis] ; Christopher G. Goetz [États-Unis] ; Anthony E. Lang [Canada] ; Esther Cubo [États-Unis] | Factor analysis of the motor section of the unified Parkinson's disease rating scale during the off‐state |
| 002643 |
Scott G. Adams [Canada] ; Anthony E. Lang [Canada] | Can the Lombard effect be used to improve low voice intensity in Parkinson's disease? |
